RxDoctor Payments Data

Elizabeth Phillips

Family · Germantown, TNNPI 1114576592

Payments from drug & device makers

$11,155in general payments, 2019–2025

Across 720 payments — averaging $15.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • AbbVie$966
  • AstraZeneca$773
  • EMD Serono, Inc.$668
  • UCB, Inc.$585
  • Amgen$555
  • plus $7K from 45 others

What the payments were for

  • Speaking & faculty fees$1111%
  • Food & beverage$10,87798%
  • Education$1671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,155 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$22,634
Medicare patients
196
Services billed
210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab45$416,525
NuplazidPimavanserin Tartrate40$195,444
Nurtec OdtRimegepant Sulfate96$119,003
GammakedImmune Globul G/Gly/Iga Avg 4616$115,904
AustedoDeutetrabenazine15$93,213
AptiomEslicarbazepine Acetate32$79,559
QuliptaAtogepant53$68,731
UbrelvyUbrogepant36$44,078
Emgality PenGalcanezumab-Gnlm44$43,112
BriviactBrivaracetam17$36,566
Aimovig AutoinjectorErenumab-Aooe32$28,336
RytaryCarbidopa/Levodopa23$22,290
XcopriCenobamate18$20,711
TrintellixVortioxetine Hydrobromide19$11,844
NeuproRotigotine14$11,451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$450$195,44440 claims
PfizerNurtec Odt$388$119,00396 claims
AbbVieQulipta, Ubrelvy$966$112,80989 claims
Teva Pharmaceuticals USA, Inc.Austedo$263$93,21315 claims
Sunovion Pharmaceuticals Inc.Aptiom$322$79,55932 claims
UCB, Inc.Briviact, Neupro$585$48,01731 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$364$23,35239 claims
SK Life Science, Inc.Xcopri$540$20,71118 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$53$11,84419 claims
Neurelis, Inc.Valtoco$49$7,99411 claims
AstraZenecaBrilinta$773$7,32115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →